You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, B-Cell

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, B-Cell Trial in San Antonio (R-Chop and Roflumilast)

Not yet recruiting
  • Lymphoma, B-Cell
  • R-Chop and Roflumilast
  • San Antonio, Texas
    Mays Cancer Center, UT Health San Antonio
Mar 31, 2023

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Relapsed/Refractory Large B-cell Lymphoma
  • (no location specified)
Oct 6, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • infusion of JY231 injection
  • Guangzhou, Guangdong, China
    Guangdong Second Provincial General Hospital
Sep 17, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 9, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

    Recruiting
    • B-cell Lymphoma
    • +5 more
    • Louisville, Kentucky
      Norton Cancer Institute
    Jan 24, 2023

    DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • Mitoxantrone Hydrochloride Liposome Injection
    • Jinan, Shandong, China
      Affiliated Cancer Hospital of Shandong First Medical University
    May 16, 2023

    Frontline of ASCT in High-risk DLBCL

    Recruiting
    • Diffuse Large B Cell Lymphoma
      • Beijing, Beijing, China
        Peking University People's Hospital
      Apr 26, 2023

      DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

      Recruiting
      • DLBCL - Diffuse Large B Cell Lymphoma
      • Follicular Lymphoma
      • Lenalidomide combined with G-CHOP (LO CHOP)
      • Xiamen, Fujian, China
        Bing Xu
      Nov 28, 2023

      CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

      Recruiting
      • CD20-positive B-cell Non-Hodgkin's Lymphoma
      • Beijing, China
        Cancer Hospital Chinese Academy of Medical Sciences
      Apr 6, 2023

      B-cell Lymphoma Trial in Stockholm, Uppsala (CAR20(NAP)-T, Cyclophosphamide, Fludarabine)

      Not yet recruiting
      • B-cell Lymphoma
      • CAR20(NAP)-T
      • +2 more
      • Stockholm, Sweden
      • +1 more
      Aug 15, 2023

      Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

      Recruiting
      • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
      • dualCAR-NK19/70 cell
      • Shanghai, Shanghai, China
        Shanghai Tongji Hospital, Tongji University School of Medicine
      Apr 24, 2023

      Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)

      Not yet recruiting
      • Lymphoma, B-Cell
      • CD19 and CD22 targeted CAR-T cells
      • Langfang, Hebei, China
        Hebei Yanda Ludaopei Hospital
      Dec 6, 2022

      Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

      Completed
      • Diffuse Large B-cell Lymphoma
        • East Hanover, New Jersey
          Novartis
        Jun 16, 2023

        Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

        Not yet recruiting
        • Cancer
        • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
        • Fludarabine (30 mg/m^2)
        • +2 more
        • (no location specified)
        Jul 25, 2023

        Relmacabtagene Autoleucel in Hematologic Malignancies

        Not yet recruiting
        • Lymphoma, B-Cell
        • +2 more
        • Relmacabtagene Autoleucel
        • Beijing, Beijing, China
        • +1 more
        Nov 15, 2023

        Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

        Not yet recruiting
        • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
        • +5 more
        • Boston, Massachusetts
        • +1 more
        Jun 28, 2023

        Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

        Not yet recruiting
        • Relapsed Non-Hodgkin Lymphoma
        • +6 more
        • (no location specified)
        Apr 12, 2023

        B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

        Not yet recruiting
        • B-cell Non Hodgkin Lymphoma
        • (no location specified)
        Aug 7, 2023

        Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

        Recruiting
        • Relapsed or Refractory B-cell Lymphoma
        • +6 more
        • Beijing, China
          Beijing Cancer Hospital
        Feb 6, 2023

        DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

        Not yet recruiting
        • Diffuse Large B-Cell Lymphoma
        • High-grade B-cell Lymphoma
        • Loncastuximab Tesirine
        • (no location specified)
        Dec 13, 2022

        Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

        Not yet recruiting
        • Diffuse Large B-cell Lymphoma
        • (no location specified)
        Mar 23, 2023